Corcept Therapeutics Incorporated Watch

from 10-Q 4 pages Tenth Amendment to Lease

from 10-Q 151 pages [Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions.] Sublease Between Zuora, Inc. and Corcept Therapeutics Incorporated 101 Redwood Shores Parkway, Redwood City, California Sublease

from 10-Q 33 pages [Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions.] Amendment No. 3 to Distribution Services Agreement

from 10-Q 4 pages Ninth Amendment to Lease

from 10-K 9 pages Corcept Therapeutics Incorporated Insider Trading Policy and Guidelines With Respect to Certain Transactions in Company Securities Purpose

from 10-Q 4 pages Corcept Therapeutics Incorporated 2012 Incentive Award Plan Restricted Stock Award Grant Notice

from 10-Q 4 pages Corcept Therapeutics Incorporated 2012 Incentive Award Plan Restricted Stock Unit Grant Notice

from 10-Q 4 pages Eighth Amendment to Lease

from 10-Q 3 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment No. 2 to Distribution Services Agreement

from 10-Q 6 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment to Distribution Services Agreement

from 10-Q 7 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Task Order Number One to Master Services Agreement Between Corcept Therapeutics Inc. and Optime Care. Inc

from 10-Q 27 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Distribution Services Agreement

from 10-Q 4 pages Corcept Therapeutics Incorporated 2012 Incentive Award Plan Restricted Stock Award Grant Notice

from 10-Q 4 pages Corcept Therapeutics Incorporated 2012 Incentive Award Plan Restricted Stock Unit Grant Notice

from 10-Q 4 pages Seventh Amendment to Lease

from 10-K 8 pages Corcept Therapeutics Incorporated 2012 Incentive Award Plan Stock Option Grant Notice

from 10-K 5 pages Severance and Change in Control Agreement

from 10-K 2 pages William Guyer Re: Offer of Employment at Corcept Therapeutics Incorporated Dear Bill: We Are Very Pleased to Invite You to Join Corcept Therapeutics Incorporated (The “Company”) in the Role of Chief Development Officer, Contingent Upon the Satisfactory Completion of a Background Check. Duties and Responsibilities. Your Initial Assignment Will Be as Chief Development Officer Reporting to Joseph K. Belanoff, M.D., Chief Executive Officer. This Offer Is for a Full-Time Position Starting September 7, 2021, or Such Other Date as We Mutually Agree. Salary. Your Initial Annual Base Salary Will Be $550,000 for Full-Time Employment, Payable in Accordance With the Company's Customary Payroll Practice. Salary Is Subject to Periodic Review and Adjustment by the Company's Management. Bonus. You Will Be Eligible for an At-Risk, Target Bonus of 45% of Your Base Salary, Payable in Accordance With the Company's Customary Payroll Practices

from 8-K 8 pages Separation Agreement

from 10-Q 4 pages Severance and Change in Control Agreement